Reviews Cambia


No reviews yet.

Cambia Drug Description
CAMBIA
(diclofenac potassium) for Oral Solution

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk
of serious cardiovascular (CV) thrombotic events, myocardial infarction,
and stroke, which can be fatal. This risk may increase with duration of
use. Patients with cardiovascular disease or risk factors for cardiovascular
disease may be at greater risk [see WARNINGS AND PRECAUTIONS].
CAMBIA is contraindicated for the treatment of peri-operative pain
in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS].

Gastrointestinal Risk

NSAIDs increase the risk of serious gastrointestinal (GI) adverse
events including bleeding, ulceration, and perforation of the stomach or
intestines, which can be fatal. These events can occur at any time during
use and without warning symptoms. Elderly patients are at greater risk for
serious gastrointestinal events [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
CAMBIA (Diclofenac Potassium for Oral Solution) is a benzeneacetic acid derivative NSAID. CAMBIA is available as a buffered soluble powder, designed to be mixed with water prior to oral administration.
CAMBIA is a white to off-white, buffered, flavored, powder for oral solution
packaged in individual unit dose packets [see HOW SUPPLIED].
The chemical name for diclofenac potassium is 2-[(2,6-dichlorophenyl)amino]
benzeneacetic acid monopotassium salt. The molecular weight of diclofenac potassium
is 334.25. Its molecular formula is C14H10Cl2NKO2,
and it has the following structural formula:








The inactive ingredients in CAMBIA include: aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glycerol behenate, mannitol, potassium bicarbonate, and saccharin sodium.
Last reviewed on RxList: 7/7/2009




Cambia Drug Description
CAMBIA
(diclofenac potassium) for Oral Solution

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk
of serious cardiovascular (CV) thrombotic events, myocardial infarction,
and stroke, which can be fatal. This risk may increase with duration of
use. Patients with cardiovascular disease or risk factors for cardiovascular
disease may be at greater risk [see WARNINGS AND PRECAUTIONS].
CAMBIA is contraindicated for the treatment of peri-operative pain
in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS].

Gastrointestinal Risk

NSAIDs increase the risk of serious gastrointestinal (GI) adverse
events including bleeding, ulceration, and perforation of the stomach or
intestines, which can be fatal. These events can occur at any time during
use and without warning symptoms. Elderly patients are at greater risk for
serious gastrointestinal events [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
CAMBIA (Diclofenac Potassium for Oral Solution) is a benzeneacetic acid derivative NSAID. CAMBIA is available as a buffered soluble powder, designed to be mixed with water prior to oral administration.
CAMBIA is a white to off-white, buffered, flavored, powder for oral solution
packaged in individual unit dose packets [see HOW SUPPLIED].
The chemical name for diclofenac potassium is 2-[(2,6-dichlorophenyl)amino]
benzeneacetic acid monopotassium salt. The molecular weight of diclofenac potassium
is 334.25. Its molecular formula is C14H10Cl2NKO2,
and it has the following structural formula:








The inactive ingredients in CAMBIA include: aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glycerol behenate, mannitol, potassium bicarbonate, and saccharin sodium.
Last reviewed on RxList: 7/7/2009




Cambia Drug Description
CAMBIA
(diclofenac potassium) for Oral Solution

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk
of serious cardiovascular (CV) thrombotic events, myocardial infarction,
and stroke, which can be fatal. This risk may increase with duration of
use. Patients with cardiovascular disease or risk factors for cardiovascular
disease may be at greater risk [see WARNINGS AND PRECAUTIONS].
CAMBIA is contraindicated for the treatment of peri-operative pain
in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS].

Gastrointestinal Risk

NSAIDs increase the risk of serious gastrointestinal (GI) adverse
events including bleeding, ulceration, and perforation of the stomach or
intestines, which can be fatal. These events can occur at any time during
use and without warning symptoms. Elderly patients are at greater risk for
serious gastrointestinal events [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
CAMBIA (Diclofenac Potassium for Oral Solution) is a benzeneacetic acid derivative NSAID. CAMBIA is available as a buffered soluble powder, designed to be mixed with water prior to oral administration.
CAMBIA is a white to off-white, buffered, flavored, powder for oral solution
packaged in individual unit dose packets [see HOW SUPPLIED].
The chemical name for diclofenac potassium is 2-[(2,6-dichlorophenyl)amino]
benzeneacetic acid monopotassium salt. The molecular weight of diclofenac potassium
is 334.25. Its molecular formula is C14H10Cl2NKO2,
and it has the following structural formula:








The inactive ingredients in CAMBIA include: aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glycerol behenate, mannitol, potassium bicarbonate, and saccharin sodium.
Last reviewed on RxList: 7/7/2009




Cambia Drug Description
CAMBIA
(diclofenac potassium) for Oral Solution

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk
of serious cardiovascular (CV) thrombotic events, myocardial infarction,
and stroke, which can be fatal. This risk may increase with duration of
use. Patients with cardiovascular disease or risk factors for cardiovascular
disease may be at greater risk [see WARNINGS AND PRECAUTIONS].
CAMBIA is contraindicated for the treatment of peri-operative pain
in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS].

Gastrointestinal Risk

NSAIDs increase the risk of serious gastrointestinal (GI) adverse
events including bleeding, ulceration, and perforation of the stomach or
intestines, which can be fatal. These events can occur at any time during
use and without warning symptoms. Elderly patients are at greater risk for
serious gastrointestinal events [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
CAMBIA (Diclofenac Potassium for Oral Solution) is a benzeneacetic acid derivative NSAID. CAMBIA is available as a buffered soluble powder, designed to be mixed with water prior to oral administration.
CAMBIA is a white to off-white, buffered, flavored, powder for oral solution
packaged in individual unit dose packets [see HOW SUPPLIED].
The chemical name for diclofenac potassium is 2-[(2,6-dichlorophenyl)amino]
benzeneacetic acid monopotassium salt. The molecular weight of diclofenac potassium
is 334.25. Its molecular formula is C14H10Cl2NKO2,
and it has the following structural formula:








The inactive ingredients in CAMBIA include: aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glycerol behenate, mannitol, potassium bicarbonate, and saccharin sodium.
Last reviewed on RxList: 7/7/2009




Cambia Drug Description
CAMBIA
(diclofenac potassium) for Oral Solution

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk
of serious cardiovascular (CV) thrombotic events, myocardial infarction,
and stroke, which can be fatal. This risk may increase with duration of
use. Patients with cardiovascular disease or risk factors for cardiovascular
disease may be at greater risk [see WARNINGS AND PRECAUTIONS].
CAMBIA is contraindicated for the treatment of peri-operative pain
in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS].

Gastrointestinal Risk

NSAIDs increase the risk of serious gastrointestinal (GI) adverse
events including bleeding, ulceration, and perforation of the stomach or
intestines, which can be fatal. These events can occur at any time during
use and without warning symptoms. Elderly patients are at greater risk for
serious gastrointestinal events [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
CAMBIA (Diclofenac Potassium for Oral Solution) is a benzeneacetic acid derivative NSAID. CAMBIA is available as a buffered soluble powder, designed to be mixed with water prior to oral administration.
CAMBIA is a white to off-white, buffered, flavored, powder for oral solution
packaged in individual unit dose packets [see HOW SUPPLIED].
The chemical name for diclofenac potassium is 2-[(2,6-dichlorophenyl)amino]
benzeneacetic acid monopotassium salt. The molecular weight of diclofenac potassium
is 334.25. Its molecular formula is C14H10Cl2NKO2,
and it has the following structural formula:








The inactive ingredients in CAMBIA include: aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glycerol behenate, mannitol, potassium bicarbonate, and saccharin sodium.
Last reviewed on RxList: 7/7/2009





Other reviews about Cambia on wordpress

CAMBIA's Patent Lens.
  by Jake Ward
Some time back, Michael Gorman of the Tech LawForum¬†had notified AT! about a company called CAMBIA, located in Canberra, Australia.¬† CAMBIA has established¬†the "Patent Lens" project;¬†a free, searchable […]


Open Source Biotechnology: CAMBIA-BiOS
  by Justin
There is an interesting article ($) in Innovations by Richard Jefferson on his efforts to promote open source innovation in biotechnology. He believes the rate and direction […]


ViroPharma Up 20% in the Past Week
  by danielteper
ViroPharma (NASDAQ:VPHM) has been up 20% last week to $9.96 a share and a market cap of $ 696 million, after the company announced a guidance for Vancocin […]


Mercedes Sosa: Todo Cambia
  by lolarusa
The magnificent Mercedes Sosa singing my favorite of her songs, Todo Cambia (Everything Changes), with thousands singing along. [youtube=http://www.youtube.com/watch?v=g8VqIFSrFUU] Here's the lyric, and a very rough translation: Todo Cambia Cambia lo […]


Paramo Cambia - A Review
  by backpackbrewer
At the prompting of Hendrik I am reviewing one of my older bits of kit, the Paramo Cambia long sleeved top. I bought the Cambia about 3 years ago […]


Cambia, todo cambia
  by asower
wow it has been a long while since I've published here. I've been living in Indiana for the past 8 weeks working on a campaign to move beyond […]


Elagua- "Cambia La Vida" EP [FamilyName]
  by Franck
‚ĚĖ Gros coup de coeur du moment: ¬†√† l'occasion du festival N.A.M.E, organis√© par une √©quipe de passionn√©s au Nord de nos contr√©s, une nouvelle recrue au sein […]


Cambia - Navigating the patent literature using PatentLens
  by libraryfit
Cambia: Navigating the patent literature using PatentLens Time: 10:30am -12pm. 10:30am for Morning Tea. Seminar runs 11am ‚Äď 12pm. Date: Thursday23 September, 2010 Location: V714 | Level 7 | Library […]


Cambia: Navigating the patent literature using PatentLens
  by Philippa Broadley
Time:¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† Seminar runs 11am ‚Äď 12pm. Morning tea at 10:30am¬† Date:¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†Thursday, 23rd¬†September, 2010¬† Location:¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† V714 | Level 7 | Library | Gardens Point¬† Registration:¬† RSVP by registering here¬† or contacting Janet […]


Cambia: Navigating the patent literature using PatentLens
  by designlibrarian
¬†INVITATION TO RESEARCHERS Time:10:30am -12pm.¬† 10:30am for Morning Tea.¬† Seminar runs 11am ‚Äď 12pm. Date:Thursday 23 September, 2010 Location:V714 | Level 7 | Library | Gardens Point Registration:RSVP by registering here¬† or […]



Other reviews about Cambia on web:

Cambia means change. Cambia is an independent non-profit institute creating new technologies, tools and paradigms to promote change and enable innovation. Welcome - Cambia - Enabling Innovation


Learn about the prescription medication Cambia (Diclofenac Potassium for Oral Solution), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Cambia (Diclofenac Potassium for Oral Solution) Drug Information ...


Cambia wood may be the first truly green lumber resource that performs better and costs less than the alternative wood species and substitute products developed to replace wood. Cambia by Greenleaf√ɬĘ√ā¬Ą√ā¬Ę :: wood. made better.


Cambia (diclofenac powder) is used to treat acute migraine headache attacks. Includes Cambia side effects, interactions and indications. Cambia Information from Drugs.com


Cambia or cambiums may refer to: Cambia, Haute-Corse, a commune in the Haute-Corse department of France; CAMBIA, an independent, international non-profit institute based in Canberra ... Cambia - Wikipedia, the free encyclopedia


Accurate, FDA approved Cambia information for healthcare professionals and patients - brought to you by Drugs.com. Cambia Official FDA information, side effects and uses.


Cambria is a natural stone surface that is elegant and practical. There is no safer surface for food preparation. If you are building or remodeling your kitchen or bath, you will ... Cambria - Natural Quartz Countertops


Cambia is a prescription NSAID used to treat migraine headaches that have already started. This eMedTV page discusses how the drug works and how it should be taken, as well as its ... Cambia


GM Foods and Bt Brinjal: Interview with Prof. Richard Jefferson, Cambia Richard Jefferson interviewed on ABC Lateline ABC Lateline, Australia April 13, 2010 BiOS Home


Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug ... FDA Approves Cambia√ɬĘ√ā¬Ą√ā¬Ę For Migraine





Featured Reviews

Reviews Hepatitis B Vaccine Recombinant

Engerix-B Drug Description ENGERIX-B® [Hepatitis B Vaccine (Recombinant)] DRUG DESCRIPTION What are the possible side effects of this vaccine (Engerix-B, Engerix-B Pediatric, Recombivax HB Adult, Recombivax HB Dialysis Formulation,...
Read More  |  Review This
Reviews Victoza

Victoza Drug Description Victoza® (liraglutide [rDNA origin]) Injection, Solution for Subcutaneous Use WARNING RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors...
Read More  |  Review This
Reviews Unoprostone isopropyl

Rescula Drug Description RESCULAâ (unoprostone isopropyl ophthalmic solution) 0.15% DRUG DESCRIPTION What are the possible side effects of unoprostone ophthalmic (Rescula)? Get emergency medical help if you have any of...
Read More  |  Review This
Reviews Promethazine Hydrochloride Suppositories

Promethazine HCl Suppositories Drug Description Promethazine Hydrochloride Suppositories, USP 12.5 mg and 25 mg DRUG DESCRIPTION What are the possible side effects of rectal promethazine (Phenadoz, Promethegan)? Get emergency medical...
Read More  |  Review This
Reviews Plan B

Plan B Drug Description Plan B® (levonorgestrel) Tablets, 0.75 mg Available without a prescription for consumers 18 and older. Rx only for women age 17 and younger For women age 17 and younger, Plan B® is a prescription-only emergency...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....